Green H - Search Results

1

Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.

Lee MY, Apellániz-Ruiz M, Johansson I, Vikingsson S, Bergmann TK, Brøsen K, Green H, Rodríguez-Antona C, Ingelman-Sundberg M. Lee MY, et al. Among authors: green h. Pharmacogenomics. 2015;16(9):929-37. doi: 10.2217/pgs.15.46. Epub 2015 Jun 26. Pharmacogenomics. 2015. PMID: 26115084

2

Pharmacogenomics of importance for paclitaxel chemotherapy.

Green H. Green H. Pharmacogenomics. 2008 Jun;9(6):671-4. doi: 10.2217/14622416.9.6.671. Pharmacogenomics. 2008. PMID: 18518845 Free article.

3

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.

Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C. Gréen H, et al. Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):130-7. doi: 10.1111/j.1742-7843.2008.00351.x. Epub 2008 Dec 16. Basic Clin Pharmacol Toxicol. 2009. PMID: 19143748 Free article.

4

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. Bergmann TK, et al. Among authors: green h. Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6. Pharmacogenomics J. 2011. PMID: 20368717

5

Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.

Gréen H, Falk IJ, Lotfi K, Paul E, Hermansson M, Rosenquist R, Paul C, Nahi H. Gréen H, et al. Pharmacogenomics J. 2012 Apr;12(2):111-8. doi: 10.1038/tpj.2010.79. Epub 2010 Oct 12. Pharmacogenomics J. 2012. PMID: 20938465

6

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.

Fransson MN, Gréen H, Litton JE, Friberg LE. Fransson MN, et al. Among authors: green h. Drug Metab Dispos. 2011 Feb;39(2):247-55. doi: 10.1124/dmd.110.035394. Epub 2010 Nov 5. Drug Metab Dispos. 2011. PMID: 21056987

7

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C. Bergmann TK, et al. Among authors: green h. Eur J Clin Pharmacol. 2011 Jul;67(7):693-700. doi: 10.1007/s00228-011-1007-6. Epub 2011 Feb 16. Eur J Clin Pharmacol. 2011. PMID: 21327421

8

Microtubule-targeting drugs and personalization of cancer treatment.

Rodríguez-Antona C, Gréen H. Rodríguez-Antona C, et al. Among authors: green h. Pharmacogenomics. 2011 Apr;12(4):449-51. doi: 10.2217/pgs.11.12. Pharmacogenomics. 2011. PMID: 21521015 No abstract available.

9

Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.

Gréen H, Khan MS, Jakobsen-Falk I, Åvall-Lundqvist E, Peterson C. Gréen H, et al. J Pharm Sci. 2011 Oct;100(10):4205-9. doi: 10.1002/jps.22680. Epub 2011 Jun 23. J Pharm Sci. 2011. PMID: 21702053 Free article.

10

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.

Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Brøsen K. Bergmann TK, et al. Among authors: green h. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25. Basic Clin Pharmacol Toxicol. 2012. PMID: 21955855 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,789 results

Search Page